BACKGROUND: This study aimed to survey urologists regarding their knowledge, acceptance and practice of active surveillance (AS) for low-risk prostate cancer.
Introduction
Due to the widespread use of PSA screening, the incidence of low-risk prostate cancer (PCa) has greatly increased over the last two decades. 1 In an attempt to postpone the potential morbidly associated with PCa treatment, active surveillance (AS) with delayed curative intent was developed as an alternative management strategy to surgery and radiation therapy for men with low-risk PCa. [2] [3] [4] [5] [6] [7] [8] Current guidelines from the American Urological Association (AUA), 9 European Association of Urology (EAU), 10 and National Comprehensive Cancer Network (NCCN) 11 propose AS as a management option for men with low-risk PCa. However, these guidelines by and large do not dictate the criteria for patient selection, schedule for patient follow-up, or triggers for delayed intervention. These shortcomings are due to the fact that to date, no study has prospectively compared the outcomes of varying published AS protocols. 12 To better understand the current state of AS within the urological community, this study aimed to survey urologists regarding their knowledge, acceptance and practice of AS for low-risk PCa.
Materials and methods
An anonymous internet-based survey was designed to assess urologists' knowledge, acceptance and practice of AS. Following institutional review board approval from the University of Miami Miller School of Medicine, urologists were surveyed via email, using addresses obtained from the AUA membership directory and from public listings on urology department websites. Affiliate and allied members of the AUA were not contacted. Before proceeding to the survey, all respondents were asked for consent, and if they completed residency training in urology. Only individuals who completed residency training were directed to complete the remainder of the survey.
Practicing urologists were then asked to provide basic demographic information, including if they completed fellowship training, their specialty of training, country of practice, number of years in practice, context of practice (i.e., university-based, community-based, or mixed), percentage of practice dedicated to the care of patients, and percentage of practice dedicated to the care of PCa patients. In addition, respondents were queried if they were familiar with AS, and if they were aware that AS differed from the approach of watchful waiting. Importantly, participants were also asked if they felt AS was ever a reasonable alternative to primary treatment for low-risk PCa. Those participants who felt AS was never a reasonable alternative were then surveyed as to the reasons why they objected to AS.
Respondents who felt AS was a reasonable management strategy were additionally asked a series of questions to determine their opinions on the appropriate criteria for AS enrollment. More specifically, urologists were surveyed as to their opinion of the minimum age for enrollment, maximum PSA level, maximum number of positive cores on a 10-12 core biopsy, highest Gleason sum in any one core, and maximum allowable volume in any one core. Additionally, respondents were queried as to how frequently they felt patients should be monitored, as well as their criteria for early re-biopsy and the initiation of treatment. Urologists were also asked if they felt there is a role for following patients with magnetic resonance imaging (MRI). Lastly, participants were asked if they personally manage patients with AS. Those urologists who indicated that they personally manage patients with AS were then surveyed for the number of patients they are presently managing.
The survey was designed and distributed using FluidSurveys.com. All results were exported to SPSS 19.0 (IBM, Somners, NY, USA) for analysis. Categorical variables were compared with the w 2 -test and continuous variables were compared with the non-parametric test of medians. When appropriate, Fisher's exact test was used for proportions of small size. A P-value of p0.05 was considered statistically significant.
Results
An invitation to complete the survey was sent to 4987 unique email addresses. In total, 425 (9%) participants successfully completed the survey and indicated that they completed urology residency training. Among these 425 respondents, 387 (91%) were both familiar with AS and aware that AS differed from watchful waiting. These individuals were the basis of further study.
Demographic information of the 387 studied respondents is detailed in Table 1 . A total of 44% of the participants completed fellowship training. Respondents have practiced urology outside of residency and/or fellowship for a median of 20 years (interquartile range [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] , and most frequently, reported practicing urology in the United States (69%) and Europe (13%). Approximately half (51%) of urologists reported practicing at least partially in a university-based setting.
A total of 370 (96%) of respondents felt AS was a reasonable alternative to primary treatment for low-risk PCa. The vast majority of these of urologists (95%) manage patients with AS and follow a median of 10 patients (interquartile range . A minority of respondents accepting of AS (6%) felt that patients with a PSA410 ng ml À1 were eligible for AS enrollment (Table 2). In addition, the majority of respondents (74%) felt that patients with a Gleason score p6 were appropriate candidates for AS. Less agreement was found for the variables of minimum age, acceptable tumor volume and number of positive cores.
Respondents lacked agreement on the timing of a second biopsy once a patient is enrolled in AS (Table 3) . Although 58% of urologists felt a second biopsy should be performed at 12 months, 30% felt this biopsy should be performed sooner. Of note, 22% advocated for a second biopsy at 6-9 months. Similarly, respondents disagreed on the timing of subsequent scheduled biopsies. More specifically, 46% of urologists felt biopsies should be performed every 12 months, whereas 12% felt biopsies should be performed every (Table 3) . Triggers for treatment included an increase in tumor grade (95%), patient reluctance to continue with surveillance (95%), increase in tumor volume (81%), rise in PSA (48%), or change in clinical exam (48%). A minority of urologists (24%) felt there is a role at this time for following patients with MRI.
In total, 17 (4%) urologists felt AS was never a reasonable management strategy for men with PCa. These 17 urologists were similar to the rest of the cohort in terms of years out of training (P ¼ 0.29), number of fellowship trained (P ¼ 1.00), location of practice (P ¼ 0.30), number practicing in a university setting (P ¼ 0.15), and percentage of practice dedicated to caring for patients with PCa (P ¼ 0.24). Most commonly, these respondents cited concerns of missing an opportunity for curative treatment (76%) and the possibility of biopsy undergrading (65%) as reasons for objecting to AS (Table 4) .
Discussion
To date, the results of a number of AS cohorts have been published. These have included data from Memorial Sloan Kettering Cancer Center, 2 Johns Hopkins University, 3 the University of California at San Francisco, 5 the University of Toronto, 7 the University of Miami, 8 and both Japanese 4 and European 6 collaborative studies. Although similar in that all of these groups aimed to safely defer treatment in men with low-volume organconfined PCa (i.e., low-risk PCa), these protocols differ in their inclusion criteria, follow-up protocols and triggers for delayed-intervention. These varied protocols have previously been reviewed in great detail by Lawrentschuk and Klotz. 12 Most noteworthy are the differences in enrollment criteria with regard to acceptable tumor volume, PSA cutoff and Gleason sum. In addition, these protocols differ in their use of PSA density, the timing of interval exams and biopsies, and the number of biopsy cores.
Despite these areas of discordance between published AS protocols, all have demonstrated the relative safety of Knowledge, acceptance and practice of active surveillance MA Gorin et al expectant management for low-risk PCa. In our own experience at the University of Miami managing 230 men on AS, only 14% of patients underwent some form of treatment for any reason at a mean follow-up of 33 months. 8 As this cohort has further matured, the treatment percentage has increased to 22% with a mean follow-up of almost 4 years (unpublished data). Of these patients, none have experienced biochemical recurrence following delayed intervention. Consistent with these data, others have reported disease-specific survivals of 97-100% at 45 years follow-up. [5] [6] [7] In light of these successful reports, the AUA, 9 EAU 10 and NCCN, 11 all independently suggest AS as an alternative to primary treatment with either surgery or radiation therapy for men with low-risk PCa. Most specific are the guidelines from the NCCN. Last updated in April 2011, these guidelines state that AS is most appropriate for men with 'very low-risk' PCa and a life expectancy of o20 years, and men with 'low-risk' PCa and a life expectancy of o10 years.
11 These guidelines define 'very low-risk' PCa as stage T1c, Gleason score p6, PSA o10 ng ml À1 , fewer than three positive cores, p50% cancer in any one core, and PSA density of o0.15 ng ml À1 g
À1
. 'Low-risk' PCa is defined as stages T1c-T2a, Gleason score p6 and PSA o10 ng ml À1 . Further, this document states that men should ideally be followed by serial PSA testing every 3-6 months, rectal exam every 6-12 months, and repeat biopsies every 12 months, with the first repeat biopsy occurring within 18 months of diagnosis. In contrast, guidelines from the AUA 9 and EAU 10 do not offer such detailed criteria for AS enrollment and follow-up.
At the present time, no prospective trials have compared outcomes between the varied AS protocols. 12 Moreover, no randomized controlled trails have compared AS to primary treatment with either surgery or radiation therapy in low-risk PCa patients. As such, there has been reluctance on the part of some to embrace the strategy of AS outside of a research protocol. A survey of AS patients by our group found that only 36% were offered AS by the urologist who first made their diagnosis. 13 Consistent with this datum is the finding that only 9% of AS-eligible patients recorded in the CaPSURE database were managed with this approach. 14 Although some have suggested this latter result is due to patient reluctance to enroll in AS, one cannot entirely discount the results of our survey. Moreover, it has been found that patients enrolled in AS report high levels of satisfaction and quality of life. [15] [16] [17] Combined, these data suggest that AS is well received by patients, and the low rate of enrollment may be primarily influenced by physician attitudes towards AS. Of note, it is well documented that patients frequently defer to their physician for aiding in the decision for PCa treatment. [18] [19] [20] The urological community's lack of prospective data comparing AS protocols, as well as lack of long-term follow-up is in part why the AUA 9 and EAU 10 guidelines fail to specify the exact parameters for AS patient enrollment, follow-up and treatment. In light of this paucity of guidance, we sought to survey the urological community of their knowledge, acceptance and practice of AS.
Among the 425 eligible respondents, 387 (91%) were familiar with AS and were aware that this management strategy differs from that of watchful waiting. Furthermore, 96% of respondent urologists felt AS was a reasonable alternative to primary treatment. The majority of these physicians manage AS patients (95%), enrolling a median of 10 patients (interquartile range .
Although respondents predominantly agreed on the criteria for AS enrollment, there was little if any agreement on the proper timing of follow-up biopsies (Table 3) . Due to the risks associated with prostate biopsy, which include urosepsis, erectile dysfunction and lower-urinary tract symptoms, [21] [22] [23] future prospective trails should focus on this area of discordance among the urological community.
Another area of discordance among respondents was the role of MRI for following AS patients. Although only a minority felt there was a role for MRI at this time (24%), this number is relatively large given the lack of data on MRI in the context of AS and the high cost of this imaging modality. 24 Additional studies are required before MRI can be recommended for the routine follow-up of AS patients.
Among the 387 respondents, only 17 (4%) felt AS was never a reasonable alternative to primary treatment. This low number is somewhat surprising given the previously reported data, which argues against physician acceptance of AS. 13, 14 However, this finding is likely to some extent an effect of 'interest bias,' as those who completed the survey are likely more interested, accepting and knowledgeable of AS. Not surprising, however, were the arguments made by this group against AS. Most commonly, respondents objected to AS because of fears of missing the opportunity for curative treatment (76%) and concerns of undergrading (65%). Additionally, 47% of respondents felt AS was unreasonable given the lack of randomized controlled trials. No urologist attributed their reluctance for AS to their lack of knowledge on this management strategy.
A major limitation of our study is the low response rate of only 9%. However, this is somewhat typical of voluntary email-based surveys. For example, previously published response rates of surveys to AUA members have been reported at o15%. 25, 26 Another limitation of this study is the fact that the respondents were heavily biased towards being fellowship trained (44%), and practicing at least partially in a university setting (51%). As such, our study cohort may not truly represent the 'average' urologist. However, despite these limitations, we believe that this work has identified several areas of discordance among a portion of the urological community requiring additional study.
Conclusions
In summary, despite a low response rate, 490% of study participants were familiar with AS and aware that this management strategy differed from watchful waiting. Of these respondents, the vast majority felt AS was a reasonable alternative to primary treatment for low-risk PCa. In addition, participants were in relative agreement that a PSA p10 ng ml À1 and Gleason score p6 define an appropriate AS candidate. In contrast, urologists found little agreement on the ideal schedule for follow-up biopsies. Future work should aim to prospectively compare AS protocols to better guide urologists in offering AS to their patients.
Knowledge, acceptance and practice of active surveillance MA Gorin et al
